Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT01761682
NCT01761682TerminatedNot Applicable

Prospective Observational Cohort Registry for Patients With Acute Lymphoblastic Leukemia at Asan Medical Center

Asan Medical Center1 site in 1 country200 target enrollmentStarted: January 2013Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Enrollment
200
Locations
1
Primary Endpoint
Overall survival
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The investigators would like to propose a prospective longitudinal observational cohort study for patients who will be diagnosed and/or treated for acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, to use the acquired data for fundamentals of other retrospective analysis.

Detailed Description

  1. Acquisition of informed concent form
  2. Data acquisition from medical record including
  • demographic / disease-associated factors
  • details of treatment, and its results
  • complications during treatment
  • genetic data
  • survival outcome (upto 10 years)
  1. Accumulation of data for 30 years
  2. Use of data for other retrospective analysis (including Asan Medical center Cell Banking basic data)

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
15 Years to — (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •All patients who are diagnosed and/or treated as acute lymphoblastic leukemia at Asan Medical Center (including biphenotypic acute leukemia with Philadelphila-positive, Burkitt leukemia/lymphoma)
  • •15 years of age and over
  • •All patients who give written consent according to guidelines at Asan Medical Center committee on human research

Exclusion Criteria

  • •Patients who refuse to give consent to registering

Outcomes

Primary Outcomes

Overall survival

Time Frame: 10 year

Secondary Outcomes

  • Relapse-free survival(10 years)
  • Event-free survival(10 years)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Dae-Young Kim

Assistant Professor

Asan Medical Center

Study Sites (1)

Loading locations...

Similar Trials

Terminated
Not Applicable
Chronic Myelod Leukemia Registry at Asan Medical CenterLeukemia, Chronic MyeloidMyeloid Leukemia, Chronic, Accelerated PhaseMyeloid Leukemia, Chronic, Chronic Phase
NCT01761695Asan Medical Center100
Recruiting
Not Applicable
Observational Study for Patients at Risk for Chronic Graft-Versus-Host DiseasecGVHD
NCT05919511Incyte Corporation1,500
Recruiting
Not Applicable
Cohort Study for Gastric MALT LymphomaGastric MALT Lymphoma
NCT06454149Seoul National University Hospital300
Completed
Not Applicable
Perioperative Symptom Study of Lung Cancer (CN-PRO-Lung 1)Patient-reported Outcomes
NCT03341377Xiaojun Yang512
Terminated
Not Applicable
The Chimerix CMX001 RegistryOutcomesSurvival Rates
NCT02167685Chimerix550